CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes ...
CytoMed Therapeutics Limited (NASDAQ: GDTC) is a healthcare/biotechnology company headquartered in Singapore that develops cell-based immunotherapies intended to be more practical and scalable than individualized autologous approaches. The company’s core strategy is to harness advanced cellular platforms built around engineered gamma delta T cell biology (and related hybrids), aiming to ...CytoMed Therapeutics Limited (NASDAQ: GDTC) is a healthcare/biotechnology company headquartered in Singapore that develops cell-based immunotherapies intended to be more practical and scalable than individualized autologous approaches. The company’s core strategy is to harness advanced cellular platforms built around engineered gamma delta T cell biology (and related hybrids), aiming to deliver an “off-the-shelf” product profile suitable for repeated dosing and broader patient access.
From a business perspective, CytoMed’s work is centered on translating proprietary technologies into investigational therapies for multiple cancer types. The company is positioned in the pre-clinical development phase, which typically involves substantial R&D investment with limited near-term commercialization. Its mission, as reflected in public materials, emphasizes producing effective and potentially more affordable cellular immunotherapies for solid and blood-based cancers—an important positioning in a market where manufacturing complexity and cost can be major barriers.
Product-wise, CytoMed’s lead candidate described in the provided materials is CTM-N2D, which uses cultivated gamma delta T cells engineered with a chimeric antigen receptor (CAR) targeting natural killer group 2D (NKG2D) ligands to enhance cancer-cell killing. The company also advances iPSC-gdNKT, which leverages induced pluripotent stem cells (iPSCs) to generate a hybrid cell product that combines characteristics of gamma delta T cells and natural killer (NK) cells. In addition, CytoMed is developing CTM-GDT, an expanded gamma delta T cell immunotherapy designed to take advantage of gamma delta T cells’ innate, broad-spectrum recognition system to address diverse cancer types.
Regarding operations and scale, the company reports a relatively small workforce for a public biopharma (about 42 full-time employees), consistent with early-stage research organizations where functions such as R&D, regulatory, and clinical operations are tightly coordinated.
On financial fundamentals and costs, the provided ttm metrics show negative profitability indicators typical of development-stage biotechnology companies (e.g., negative operating and net margins) and negative free cash flow measures, reflecting ongoing spending on R&D and related operating costs without revenue generation at scale. Liquidity ratios appear relatively strong in the snapshot (e.g., a comparatively high current ratio), which can be consistent with capital raised through public markets and/or prior financing during pre-commercial development.
Key people include Chee Kong Choo, listed as CEO in the dataset (also referenced in public team/insider context), who leads the company’s strategic and development direction. For investors and stakeholders, CytoMed’s “wishes” or near-term priorities in this lifecycle are generally to progress candidates through further pre-clinical/clinical milestones, strengthen manufacturing readiness for off-the-shelf supply, and broaden the evidence base demonstrating safety and efficacy across targeted cancer indications.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$319201
+359.3%
-18.1%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-3.9M
-55.6%
-99.3%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
-277.7%
-468.5%
-492.0%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-1416.0%
+68.6%
-335.2%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-1227.1%
+66.1%
-143.4%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-4.4M
-7.1%
-96.6%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-1378.6%
+76.7%
-140.0%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
7.4%
+42.7%
0.0%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
5.17x
-47.8%
0.0%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
